» Articles » PMID: 27027417

Surveillance Rates for Hepatocellular Carcinoma Among Patients with Cirrhosis, Chronic Hepatitis B, and Chronic Hepatitis C Based on Japanese Claims Database

Overview
Journal Hepatol Res
Specialty Gastroenterology
Date 2016 Mar 31
PMID 27027417
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Surveillance is recommended for patients with risk of hepatocellular carcinoma (HCC) such as viral hepatitis and liver cirrhosis (LC). Although populations are at higher risk in Asia, surveillance rates have not been evaluated in those countries. Therefore, we aimed to examine surveillance rates for HCC and to compare predictors for surveillance among each type of liver disease in Japan.

Methods: We carried out an observational study using the medical claims data of Japan. A total of 4713 patients who were diagnosed with LC, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection were followed for 12 months. We described surveillance rates in patients with HBV or HCV infection or non-viral LC and evaluated potential predictors for follow-up surveillance among them by using multivariable logistic regression analysis, in which we set explanatory variables as sex, age, medical facility, HBV or HCV infection, and LC.

Results: The HCC surveillance rate during follow-up was 42.3% among patients with chronic viral hepatitis, 56.5% with viral cirrhosis and 26.0%, with non-viral LC. Significant predictors for follow-up surveillance were presence of LC and hospital visits. Hepatitis B virus-infected patients aged <50 years and HCV-infected patients aged ≥50 years were more likely to undergo exams, that is, different tendencies between HBV and HCV patients were shown.

Conclusions: Follow-up surveillance for HCC was not adequately carried out among patients at risk for HCC in Japan, despite of recommendation in guidelines. In future, methodological research might be needed to increase surveillance rates for HCC in patients with chronic hepatitis or those who received treatment at a clinic.

Citing Articles

Real-World Epidemiology, Clinical and Economic Burden of Chronic Hepatitis B in Japan: A Retrospective Study Using JMDC Claims Database.

Umemura T, Wattanakamolkul K, Nakayama Y, Takahashi Y, Sbarigia U, KyungHwa L Infect Dis Ther. 2023; 12(5):1337-1349.

PMID: 37067724 PMC: 10229495. DOI: 10.1007/s40121-023-00795-0.


Data resource profile: JMDC claims database sourced from health insurance societies.

Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T J Gen Fam Med. 2021; 22(3):118-127.

PMID: 33977008 PMC: 8090843. DOI: 10.1002/jgf2.422.


A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk.

Frenette C, Isaacson A, Bargellini I, Saab S, Singal A Mayo Clin Proc Innov Qual Outcomes. 2019; 3(3):302-310.

PMID: 31485568 PMC: 6713857. DOI: 10.1016/j.mayocpiqo.2019.04.005.


Database analysis of patients with hepatocellular carcinoma and treatment flow in early and advanced stages.

Akada K, Koyama N, Taniguchi S, Miura Y, Aoshima K Pharmacol Res Perspect. 2019; 7(4):e00486.

PMID: 31249691 PMC: 6584471. DOI: 10.1002/prp2.486.


Hepatocellular Carcinoma Surveillance-Experience from Croatian Referral Centre for Chronic Liver Diseases.

Majerovic M, Jelakovic M, Premuzic M, Knezevic Stromar I, Radic D, Mance M J Gastrointest Cancer. 2017; 50(1):48-53.

PMID: 29127665 DOI: 10.1007/s12029-017-0011-1.